Ryan J. Sullivan

1999–2025 年に発表

258
論文数
46,334
被引用数
93
h 指数
239
i10 指数

被引用数

Ryan J. Sullivan の年別被引用数1999 年: 被引用 1 件2000 年: 被引用 4 件2001 年: 被引用 6 件2002 年: 被引用 3 件2003 年: 被引用 9 件2004 年: 被引用 6 件2005 年: 被引用 10 件2006 年: 被引用 10 件2007 年: 被引用 9 件2008 年: 被引用 9 件2009 年: 被引用 8 件2010 年: 被引用 13 件2011 年: 被引用 10 件2012 年: 被引用 20 件2013 年: 被引用 105 件2014 年: 被引用 183 件2015 年: 被引用 212 件2016 年: 被引用 243 件2017 年: 被引用 450 件2018 年: 被引用 550 件2019 年: 被引用 1,832 件2020 年: 被引用 2,648 件2021 年: 被引用 2,893 件2022 年: 被引用 2,798 件2023 年: 被引用 2,168 件2024 年: 被引用 3,645 件2025 年: 被引用 2,019 件2026 年: 被引用 61 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 7,010 件、この内訳の 28.2%中国: 引用元論文 3,520 件、この内訳の 14.2%イギリス: 引用元論文 1,368 件、この内訳の 5.5%ドイツ: 引用元論文 1,333 件、この内訳の 5.4%イタリア: 引用元論文 1,190 件、この内訳の 4.8%フランス: 引用元論文 1,026 件、この内訳の 4.1%オーストラリア: 引用元論文 800 件、この内訳の 3.2%カナダ: 引用元論文 714 件、この内訳の 2.9%スイス: 引用元論文 685 件、この内訳の 2.8%日本: 引用元論文 668 件、この内訳の 2.7%オランダ: 引用元論文 658 件、この内訳の 2.6%スペイン: 引用元論文 647 件、この内訳の 2.6%
0%28.2%その他 21%

分野

  • Medicine59.4%
  • Biochemistry, Genetics and Molecular Biology26.1%
  • Immunology and Microbiology9.6%
  • Engineering1.4%
  • Neuroscience0.7%
  • Computer Science0.5%
  • その他2.3%

トピック

  • Cancer Immunotherapy and Biomarkers13.7%
  • Immunotherapy and Immune Responses5.5%
  • CAR-T cell therapy research5%
  • Immune Cell Function and Interaction3.6%
  • Single-cell and spatial transcriptomics3.5%
  • Melanoma and MAPK Pathways3.2%
  • その他65.5%

共著者

全論文

検索で開く
  1. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dennie T. Frederick, Judit Jané‐Valbuena, Charles H. Yoon, Orit Rozenblatt–Rosen, Alex K. Shalek, Aviv Regev, Levi A. Garraway - Science 2016 被引用: 5,391

  2. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jennifer A. Wargo, Genevieve M. Boland, Ryan J. Sullivan, Gad Getz, Nir Hacohen - Cell 2018 被引用: 2,103

  3. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2018 被引用: 2,609

  4. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michelle Brown, Praveen Aanur, Robert Meehan, Tal Zaks - The Lancet 2024 被引用: 739

  5. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Israel Cañadas, Bastian Schilling, Adam N.R. Cartwright, Adrienne Luoma, Shruti Malu, Patrick Hwu, Chantale Bernatchez, Marie-Andrée Forget, David A. Barbie, Alex K. Shalek, Itay Tirosh, Peter K. Sorger, Kai W. Wucherpfennig, Eliezer M. Van Allen, Dirk Schadendorf, Bruce E. Johnson, Asaf Rotem, Orit Rozenblatt–Rosen, Levi A. Garraway, Charles H. Yoon, Benjamin Izar, Aviv Regev - Cell 2018 被引用: 1,482

  6. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 被引用: 878

  7. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

    著者: , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2018 被引用: 1,542

  8. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James M. McFarland, Ewa Sicińska, Tyler Jacks, Ryan J. Sullivan, Geoffrey I. Shapiro, Thomas E. Clancy, Kimberly Perez, Douglas A. Rubinson, Kimmie Ng, James M. Cleary, Lorin Crawford, Scott R. Manalis, Jonathan A. Nowak, Brian M. Wolpin, William C. Hahn, Andrew J. Aguirre, Alex K. Shalek - Cell 2021 被引用: 614

  9. Resistance to checkpoint blockade therapy through inactivation of antigen presentation

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nir Hacohen - Nature Communications 2017 被引用: 1,001

  10. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque

    著者: , , , , , , , , , , , , , , , , , , , - Circulation 2020 被引用: 537

  11. Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy

    著者: , , , , , , , , , , , , , , , - Cell 2020 被引用: 488

  12. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

    著者: , , , , , , , , , , , , , - Nature Medicine 2018 被引用: 817

  13. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

    著者: , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2016 被引用: 1,241

  14. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 261

  15. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

    著者: , , , , , , , , , , , , , , , , , , , , - Nature Communications 2016 被引用: 572

  16. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2020 被引用: 280

  17. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies

    著者: , - Nature Reviews Drug Discovery 2021 被引用: 275

  18. The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2020 被引用: 226

  19. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2017 被引用: 418

  20. Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor–Associated Myocarditis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alexander R. Lyon, Paaladinesh Thavendiranathan, Justine V. Cohen, Kerry L. Reynolds, Michael G. Fradley, Tomas G. Neilan - Circulation 2020 被引用: 267

  21. High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma

    著者: , , , , , , , - Cancer 2018 被引用: 483

  22. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Immunology 2019 被引用: 333

  23. Clusters of circulating tumor cells traverse capillary-sized vessels

    著者: , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2016 被引用: 496

  24. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gagan Sahni, Carlo G. Tocchetti, Valentina Mercurio, Michael Mahmoudi, Donald P. Lawrence, Kerry L. Reynolds, Jonathan W. Weinsaft, A. John Baksi, Stéphane Éderhy, John D. Groarke, Alexander R. Lyon, Michael G. Fradley, Paaladinesh Thavendiranathan, Tomas G. Neilan - European Heart Journal 2020 被引用: 343